Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a clinical trial to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standards supportive care in an outpatient setting.
Description: The primary efficacy outcome measure evaluates change in SARS-CoV-2 viral load at Day 4 from Day 1, of LAM-002A or placebo-treated participants. SARS-CoV-2 viral load will be measured by a qRT-PCR test of nasopharyngeal samples. Analysis will focus on log10 viral load on Day 4 compared to baseline viral load at Day 1 in participants with baseline viral load >100,000 copies/mL
Measure: Viral Load Change Time: 4 DaysDescription: The proportion of LAM 002A-treated participants who develop TEAEs compared to placebo
Measure: Safety and Tolerability Time: 28 DaysDescription: The proportion of participants treated with LAM-002A compared to placebo, who have disease progression by Day 28 as defined by the occurrence of: Hospitalization Death
Measure: Clinical Efficacy Time: 28 DaysDescription: To evaluate change in COVID-19 clinical status, as defined by the ordinal scale, of participants treated with LAM-002A compared to placebo at Day 28, in participants who become hospitalized and continue LAM-002A/placebo treatment, based on the following scores: Not in the hospital Hospitalized, requiring low flow supplemental oxygen (such as nasal cannula) Hospitalized, not on invasive ventilation (such as 100% non-rebreather, BIPAP), (pre-ICU) Hospitalized, in the ICU, on invasive ventilation or ECMO Dead
Measure: Change in COVID-19 Clinical Status Time: 28 DaysDescription: To compare the proportion of participants at or above 95% oxygen saturation (O2 sat) between LAM-002A versus placebo treatment groups as measured on Days 1, 4, and 11.
Measure: Oxygen Saturation Time: 11 DaysDescription: To potentially evaluate the change from baseline (Day 1, Pre-dose) of SARS-CoV-2 viral load as measured by a qRT-PCR test from saliva samples on Day 4, compared between the LAM-002A arm and the placebo arm in participants with a baseline viral load >100,000 copies/mL
Measure: Viral Clearance Time: 4 DaysDescription: To potentially evaluate the change from baseline (Day 1, Pre-dose) of SARS-CoV-2 viral load as measured by a qRT-PCR test from saliva samples on Day 11, compared between the LAM-002A arm and the placebo arm in participants with a baseline viral load >100,000 copies/mL
Measure: Viral Clearance Time: 11 DaysDescription: To potentially evaluate the change from baseline (Day 1, Pre-dose) of SARS-CoV-2 viral load as measured by a qRT-PCR test from saliva samples on Day 28, compared between the LAM-002A arm and the placebo arm in participants with a baseline viral load >100,000 copies/mL
Measure: Viral Clearance Time: 28 DaysDescription: To potentially evaluate the difference in SARS-CoV-2 viral load as measured by a qRT-PCR test from saliva samples based on AUC(Day1-Day11), between the LAM-002A arm and the placebo arm in participants with a baseline viral load >100,000 copies/mL.
Measure: Viral Clearance AUC Time: 11 DaysDescription: To potentially evaluate the difference in SARS-CoV-2 viral load as measured by a qRT-PCR test from saliva samples based on AUC(Day1-Day28), between the LAM-002A arm and the placebo arm in participants with a baseline viral load >100,000 copies/mL.
Measure: Viral Clearance AUC Time: 28 DaysDescription: To potentially evaluate the difference in proportion of participants with a SARS-CoV-2 viral load less than
Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports